Lixte Biotech

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company. It uses biomarker technology to identify enzyme targets and designs novel compounds to attack those targets. The firm focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases, and the LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in Pasadena, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Pasadena, CA.

Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining Immunotherapy and Chemotherapy for Untreated Small Cell Lung Cancer as it Does in Animal Models

LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope's Ongoing Phase 1b Clinical Trial in Evaluating Lixte's Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer

THE RESEARCH SHOWS THAT PP2A, THE TARGET OF LIXTE'S LEAD CLINICAL COMPOUND, LB-100 , WHEN DEFICIENT, ENHANCES EFFECTS OF IMMUN E CHECKPOINT BLOCKADE OF CANCER BY A PREVIOUSLY UNAPPRECIATED MECHANISM

LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH

Vinco Ventures

Sorrento Therapeutics Inc

Here's some tips for sustainably investing in penny stocks The post How to Sustainably Invest in Penny Stocks  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Sustainably Invest in Penny Stocks

Lixte Biotech (NASDAQ: LIXT ) stock is dropping on Wednesday but it's not due to any negative news from the drug discovery company. Instead, it's the result of shares retreating after a massive rally on Wednesday.

Why Is Lixte Biotech (LIXT) Stock Down 29% Today?

Cano Health

iBio

Are penny stocks able to provide full time income? The post Can Trading Penny Stocks Be a Full Time Job?

Can Trading Penny Stocks Be a Full Time Job?

-- THE STUDY ESTABLISH ES A NOVEL CONCEPT OF “TUMOR SUPPRESSIVE DRUG RESISTANCE”

LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

Presentation to be Broadcast Wednesday December 7 at 3:30 p.m. EST/12:30 p.m.

LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference

PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced that the Spanish Agency for Medicines and Health Products (Agencia Española de Medicamentos y Productos Sanitarios, AEMPS) has authorized a Phase 1b/randomized Phase 2 study of LB-100, the Company's lead clinical compound, plus doxorubicin versus doxorubicin alone, the global standard for initial treatment of advanced soft tissue sarcomas (ASTS).

LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP

PASADENA, CA, June 21, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced the appointment of Bas van der Baan to its Board of Directors. He will serve as an independent director.

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

Bernards is internationally recognized for his contributions to the development of effective anti-cancer drugs from their earliest stages through clinical use

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

Harbor Custom Development, Inc.

Medavail Holdings Inc

Redbox Entertainment

Camping World Hlds

Short squeeze stocks are in focus today following another bearish week for the markets. Here are Fintel's top short squeeze candidates.

Short Squeeze Stocks: RDBX, MDVL and 3 Others Experts Think Are Ready to Pop

Sonim Technologies Inc

Are these trending penny stocks on your watchlist in May? The post Trending Penny Stocks to Watch As the First Week of May Ends  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trending Penny Stocks to Watch As the First Week of May Ends

Aterian

Zymeworks Inc

Veru

Short squeeze stocks are once again in focus this week as Fintel released its weekly Short Squeeze Leaderboard report. Let's take a look.

Short Squeeze Stocks: HCDI, ZYME and 3 Others Experts Think Are Ready to Pop

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru Joins

PolarityTE Inc

RLX Technology

Check these three penny stocks out for your watchlist right now The post Penny Stocks to Buy For Your Watchlist Next Week  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks to Buy For Your Watchlist Next Week

PASADENA, CA, April 14, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certain institutional and accredited investors for $5.8 million of common stock. The Company issued a total of 2,900,000 shares of common stock at a purchase price of $2.00 per share.

LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

JERSEY CITY, N.J., April 14, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced the completion of the purchase and sale of 2,900,000 shares of LIXTE Biotechnology Holdings, Inc.'s (Nasdaq: LIXT) common stock, at a purchase price of $2.00 per share, in a registered direct offering for total gross proceeds of $5.8 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

WallachBeth Capital Announces Completion of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct Offering

LOS ANGELES--(BUSINESS WIRE)--WestPark Capital, Inc., a full-services investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment with certain institutional investors for $5.8 million of common stock. The Company issued a total of 2,900,000 shares of common stock, at a purchase price

WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)

$5.8 Million Registered Direct Offering Priced At-The-Market JERSEY CITY, N.J. , April 13, 2022  /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, has entered into definitive agreements for the purchase and sale of 2,900,000 shares of LIXTE's common stock at a purchase price of $2.00 per share in a registered direct offering.

WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)

LIXT stock has surged by 200% on positive pre-clinical trials news. However, it has a long way to go before its drug candidate is approved.

LIXT Stock Gets 200%+ Lift, Don't Get Caught on the Way Down

Actinium Pharmaceuticals

Qualigen Therapeutics

Biotech stocks are up today amid an influx of positive news. Here's what investors need to know as these small companies skyrocket.

Biotech Stocks News: What's Going on With LIXT, PTE, QLGN and ATNM Stocks Today?

PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has entered into definitive agreements for the purchase and sale of 2,900,000 shares of LIXTE's common stock, at a purchase price of $2.00 per share, in a registered direct offering. The closing of the offering is expected to occur on or about April 14, 2022, subject to the satisfaction of customary closing conditions.

LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market

Lixte Biotechnology (LIXT) stock is rocketing higher on Tuesday after the company revealed pre-clinical results for one of its treatments. The post Why Is Lixte Biotechnology (LIXT) Stock Up Today?

Why Is Lixte Biotechnology (LIXT) Stock Up Today?

LIXTE Biotechnology Holdings Inc (NASDAQ: LIXT) shares are trading higher after the presentation of new data from drug combinations of LIXTE's lead clinical cancer compound, LB-100. Data were shared at the Annual Meeting of the American Association for Cancer Research (AACR).

Lixte Biotech Shares Jumps Over 100% On Promising Preclinical Data From Lead Program In KRAS-Mutant Cancers

BioCardia Inc.

Here's what you need to know about buying penny stocks on April 12th The post Top Penny Stocks to Buy? 3 As Stock Futures Climb Before Market Open appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Lixte Biotech Stock (LIXT)